MINNEAPOLIS, Jan. 08, 2024 (GLOBE NEWSWIRE) -- National Marrow Donor Program®/Be The Match®, which operates the world’s most diverse registry of blood stem cell and marrow donors, is proud to unveil its new organizational name and brand: NMDP℠. Find cures. Save lives. What began as the national registry of unrelated bone marrow donors 37 years ago has grown and evolved into a global nonprofit leader in cell therapy driving research to improve outcomes for patients diagnosed with more than 75 blood cancers and disorders.

明尼阿波利斯，2024年1月8日（环球通讯社）--国家骨髓捐赠者计划®/Be The Match®，运营着世界上最多样化的造血干细胞和骨髓捐赠者登记册，很自豪地推出了新的组织名称和品牌：NMDP℠. 寻找治疗方法。拯救生命。37年前，国家非亲缘骨髓捐赠者登记处（national registry of unrelated bone marrow捐助者）成立，现已发展成为全球非营利细胞治疗领域的领导者，推动研究，以改善被诊断患有75多种血癌和疾病的患者的预后。

The new name and brand align with this evolution, harnessing the full breadth of NMDP’s expertise, programs, and partnerships worldwide – now and in the years to come. “Our organization has been known by many names – National Marrow Donor Program, the national registry, Be The Match – but we have always operated with a single purpose: saving lives through cell therapy.

新的名称和品牌与这一演变相一致，充分利用了NMDP在全球范围内的专业知识、计划和合作伙伴关系，无论是现在还是未来几年。“我们的组织以许多名字闻名——国家骨髓捐赠者计划、国家登记处，是最合适的组织——但我们始终以一个单一的目的运作：通过细胞疗法挽救生命。

Over nearly four decades, the world has evolved, and so have we, expanding our global footprint, advancing research throughout the cell therapy ecosystem and impacting more people’s lives,” said Amy Ronneberg, CEO, NMDP. “As we reflect on all we have achieved and the advancements we hope to realize from here, the time is right to unify our name and brands to reflect this evolution.” NMDP’s vision is to create a world in which every patient can receive their life-saving cell therapy.

NMDP首席执行官艾米·朗内伯格（AmyRonneberg）表示：“近四十年来，世界不断发展，我们也在不断扩大全球足迹，推动整个细胞治疗生态系统的研究，并影响更多人的生活。”。“当我们反思我们取得的一切成就和我们希望从这里取得的进步时，现在是时候统一我们的名字和品牌来反映这一演变了。”NMDP的愿景是创造一个每个患者都可以接受挽救生命的细胞疗法的世界。

While the organization has facilitated more than 125,000 blood stem cell and marrow transplants since its founding, there are still thousands of patients each year who face barriers to treatment. Two key strategic focus areas shaping the future of the organization include innovative research to advance standards of care and improve patient outcomes; and leveraging that same research with patient advocacy to p.

虽然该组织自成立以来已经促进了超过125000例造血干细胞和骨髓移植，但每年仍有数千名患者面临治疗障碍。塑造组织未来的两个关键战略重点领域包括创新研究，以提高护理标准和改善患者预后；并将同样的研究与患者倡导相结合。